<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="166568">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01986998</url>
  </required_header>
  <id_info>
    <org_study_id>oral-CORTEM</org_study_id>
    <secondary_id>2012-001965-34</secondary_id>
    <nct_id>NCT01986998</nct_id>
  </id_info>
  <brief_title>Study to Compare the Clinical and Radiological Efficacy of 625 mg Versus 1250 mg of Oral Methylprednisolone in Patients With Multiple Sclerosis in Relapse</brief_title>
  <official_title>Multicenter, Randomized, Double-blind Clinical Trial to Compare the Clinical and Radiological Efficacy of 625 mg Versus 1250 mg of Oral Methylprednisolone in Patients With Multiple Sclerosis in Relapse.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Germans Trias i Pujol Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Germans Trias i Pujol Hospital</source>
  <oversight_info>
    <authority>Spain: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators plan to carry out a multicenter randomized clinical trial and MRI study of
      high-dose oMP (1250mg/day for 3 days) versus lower-high dose oMP (625mg/day for 3 days) and
      demonstrated that lower-high dose of oMP is as effective as a higher-high dose of oMP in
      acute relapse of multiple sclerosis (MS). If it is shown, our purpose is to promote this
      therapeutic regimen because it is safer for the patient (less adverse effects) and less
      costly to the healthcare system.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      DESIGN: Phase IV clinical trial, multicentre, randomized and double blind, active drug
      controlled and parallel groups.  Patients will be randomised to a high dose of oMP vs a
      lower-high dose of oral Methylprednisolone (oMP).

      SETTING: 9 MS Units from 9 hospitals of the public health system with extensive experience
      in treating patients with MS and design and participation in clinical trials.

      PROCEDURES:

      After signing the informed consent, the inclusion and exclusion criteria specific to the
      study will be checked. The diagnostic test will take place prior to administration of study
      medication and will include medical history, neurological examination (EDSS measurement)
      taking of vital signs (blood pressure, heart rate and body temperature) and MRI. Concomitant
      medication will be checked. Patients will be instructed about the requirements during the
      study.

      The trial medication will be provided to the patient in the medical office (day 1 of the
      study), where the patient will remain until the intake. This action will be repeated the
      following 2 days. The latency period from the beginning of the relapse until the start of
      treatment will be registered. The questionnaires of tolerance will be completed.

      Day 1 will be defined as the first day on which first dose of oMP is administered.

      Once given the treatment under study, the adverse events reported spontaneously or after
      question will be collected.

      There will be follow-up visits at 7 and 28 days, and 3 months after initiation of treatment.
      At baseline, prior to drug administration, and on days 7 and 28 after initiation of
      treatment, a brain MRI with and without contrast will be performed. In case of adverse
      events or laboratory abnormalities, the patients could have an accessory follow-up visits
      until resolution.

      Randomization will be performed on the day of administration (day 1)

      The treatments are:

      Group A: Methylprednisolone 1250 mg / day orally for 3 days Group B: Methylprednisolone
      625 mg / day orally for 3 days
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">July 2015</completion_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Disability scale of Kurtzke EDSS score</measure>
    <time_frame>up to day 91</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events / tolerability</measure>
    <time_frame>Baseline and day 29</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disability scale of Kurtzke EDSS score</measure>
    <time_frame>Baseline and day 8</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number and volume of active lesions (measured by the T2 or gadolinium enhancement), the number of new active lesions and the percentage of active lesions at baseline that becomes black holes</measure>
    <time_frame>day -1 and day 29</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events / tolerability</measure>
    <time_frame>Baseline and day 8</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Questionnaire MSQOL-54</measure>
    <time_frame>Baseline and day 8</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Questionnaire MSQOL-54</measure>
    <time_frame>Baseline and day 29</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>oMP 1250 mg: Group A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Methylprednisolone 1250 mg/24h x3 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>oMP 625 mg: Group B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Methylprednisolone oral 625 mg/24h x3 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone 1250 mg/24h x3 days</intervention_name>
    <description>Oral Methylprednisolone 1.250 mg daily, over 1 hour and during 3 consecutive days. 13 capsules will be administered (12 capsules of 100 mg and 1 capsule of 50 mg)</description>
    <arm_group_label>oMP 1250 mg: Group A</arm_group_label>
    <other_name>Group A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Methylprednisolone 625 mg/24h x3 days</intervention_name>
    <description>Oral Methylprednisolone 625 mg daily, over 1 hour and during 3 consecutive days. 13 capsules will be administered (6 capsules of 100 mg, 1 capsule of 25 mg and 6 capsules of placebo with the same appearance of capsules of 100 mg)</description>
    <arm_group_label>oMP 625 mg: Group B</arm_group_label>
    <other_name>Group B</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Relapsing-remitting MS (Mc Donald criteria 2010) regardless being under
             immunomodulatory treatment

          2. EDSS (previous to relapse) between 0 and 5

          3. MS relapse of moderate intensity (EDSS increase from 1 to 2.5 points) or severe
             intensity (EDSS increase &gt; 3 points)

               -  If EDSS previous relapse is available:

                    -  optic neuritis, myelitis or brainstem relapse: the EDSS should increase of
                       1 point in visual, pyramidal or brainstem system function

                    -  relapse in other location or uncertain location: the EDSS should increase
                       at least 1 point

               -  If EDSS previous relapse is not available:

                    -  optic neuritis, myelitis or brainstem relapse: the visual, pyramidal or
                       brainstem system function should be &gt; 2 points.

                    -  relapse in other location or uncertain location: EDSS should be &gt; 2 points

          4. Recent clinical relapse onset (&lt;15 days) without fever

          5. One month of clinical stability prior to relapse

          6. Signed informed consent

          7. Capacity to ingest the medication.

        Exclusion Criteria:

          1. Doubts about the diagnosis of multiple sclerosis

          2. First episode of inflammatory neurological disease

          3. Secondary progressive MS or primary progressive MS

          4. Symptoms with lasted less than 24 hours of evolution

          5. Any degree of subjective or objective remission

          6. Treatment with corticosteroids during the previous 30 days

          7. Patients with immunosuppressive treatment (azathioprine, mitoxantrone,
             cyclophosphamide) or Natalizumab or Fingolimod

          8. Pregnancy or breastfeeding women or women of childbearing potential not using
             contraceptive measures

          9. Diseases with a contraindication of treatment with corticosteroids

         10. History of serious adverse reaction or hypersensitivity to drugs related to study
             medication

         11. Patients who could not be regular MRI, not collaborators or who requires anesthesia.

         12. Lactose intolerance

         13. Patients with allergies to contrast used in MRI

         14. Patients with renal impairment
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cristina Ramo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Germans Trias i Pujol Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cristina Ramo, MD</last_name>
    <phone>93 497 88 62</phone>
    <email>cramot@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Universitari Germans Trias I Pujol de</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristina Ramo, MD</last_name>
      <phone>93 497 88 62</phone>
      <email>cramot@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Cristina Ramo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joan Costa, MD,PhDClinical Pharmacologist</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pilar Giner, PhDPharmacist</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laia Grau, MD. PhDNeurologist</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eva Montané, MDClinical Pharmacologist</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eva Martínez-Cáceres, MD,PhDImmunologist</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Figueres</name>
      <address>
        <city>Figueres</city>
        <state>Girona</state>
        <zip>17600</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olga Carmona, MD,PhD</last_name>
      <email>ocarmona@salutemporda.cat</email>
    </contact>
    <investigator>
      <last_name>Olga Carmona, MD, PhDNeurologist</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic I Provincial de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yolanda Blanco, MD,PhD</last_name>
      <phone>93 227 54 12</phone>
      <email>YBLANCO@clinic.ub.es</email>
    </contact>
    <investigator>
      <last_name>Yolanda Blanco, MD, PhDNeurologist</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Mataró</name>
      <address>
        <city>Barcelona</city>
        <zip>08034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Cano, MD</last_name>
      <email>acano@csdm.cat</email>
    </contact>
    <investigator>
      <last_name>Antonio Cano, MD. PhDNeurologist</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elvira Munteis, MD</last_name>
      <email>EMunteis@parcdesalutmar.cat</email>
    </contact>
    <investigator>
      <last_name>Elvira Munteis, MDNeurologist</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Sant Joan Despí Moisés Broggi</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Esther del Moral, MD,PhD</last_name>
      <email>estermoral@yahoo.es</email>
    </contact>
    <investigator>
      <last_name>Esther del Moral, MD, PhDNeurologist</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari de Girona Dr. Josep Trueta</name>
      <address>
        <city>Girona</city>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lluis Ramió, MD</last_name>
      <email>llramio.girona.ics@gencat.cat</email>
    </contact>
    <investigator>
      <last_name>Lluis Ramió, MD. PhDNeurologist</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Arnau de Vilanova de Lleida</name>
      <address>
        <city>Lleida</city>
        <zip>25198</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis Brieva, MD</last_name>
      <email>brievaluis@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Luis Brieva, MD. PhDNeurologist</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Sant Pau I Santa Tecla</name>
      <address>
        <city>Tarragona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jordi Batlle, MD</last_name>
      <email>jbatlle@xarxatecla.cat</email>
    </contact>
    <investigator>
      <last_name>Jordi Batlle, MD. PhDNeurologist</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 18, 2013</lastchanged_date>
  <firstreceived_date>January 11, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Germans Trias i Pujol Hospital</investigator_affiliation>
    <investigator_full_name>Cristina Ramo</investigator_full_name>
    <investigator_title>Cristina Ramo</investigator_title>
  </responsible_party>
  <keyword>Multiple sclerosis relapse</keyword>
  <keyword>oral methylprednisolone</keyword>
  <keyword>EDSS</keyword>
  <keyword>gadolinium</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
